¼¿ï¾Æ»êº´¿ø ´ëÇѺÎÀÎÁ¾¾çÇÐȸ 2019 KGOG Winter Workshop Ovarian Cancer : 2019-02-17±³À°ÀÏÀÚ : 2019-02-17
±³À°Àå¼Ò : ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ´ë°´ç
±³À°ÁÖÁ¦ :
2019 KGOG Winter Workshop Ovarian CancerÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸
´ã´çÀÚ : ±èÀμ÷
¿¬¶ôó : 02-512-5420
À̸ÞÀÏ :
koreagynonco@hanmail.net ±³À°Á¾·ù : »êºÎÀΰú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 7 ½Ã°£ 35ºÐ
¼¼ºÎ¼ö°·á : 30,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 08:55~09:00 Orientation °¼®¹ü(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 09:00~09:15 Review of ESMO-ESGO consensus guideline of ovarian cancer ÃÖÇöÁø(Á߾Ӵ뺴¿ø)
±³À°½Ã°£ 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 09:15~09:30 2018 Best international research paper on ovarian cancer ¼ÛÅÂÁ¾(°ºÏ»ï¼ºº´¿ø)
±³À°½Ã°£ 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 09:30~09:45 2018 Best Korean research paper on ovarian cancer ¹èÀ縸(ÇѾç´ëº´¿ø)
Åä·Ð 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 09:45~09:55 Discussion ()
ÈÞ½Ä 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 09:55~10:15 Coffee Break ()
±³À°½Ã°£ 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 10:15~10:45 How can we provide optimal treatment outcome for BRCA mutation OC patients? Áö¿ëÀÏ(ÇØ¿î´ë¹éº´¿ø)
±³À°½Ã°£ 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 10:45~11:15 How can we conduct early testing and high quality testing of BRCA mutation? ¼ºÃ¢¿Á(¼¿ï¾Æ»êº´¿ø)
Åä·Ð 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 11:15~11:25 Discussion ()
±³À°½Ã°£ 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 11:25~11:55 IO Drug adverse event overview ¼±Á¾¹«(»ï¼º¼¿ïº´¿ø)
Åä·Ð 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 11:55~12:05 Discussion ()
±³À°½Ã°£ 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 12:05~12:15 Case 1 ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 12:15~12:25 Case 2 ÃÖ¹Îö(ºÐ´çÂ÷º´¿ø)
Åä·Ð 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 12:25~12:35 Discussion ()
½Ä»ç 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 12:35~13:30 Lunch ()
±³À°½Ã°£ 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 13:30~13:45 Hormone treatment in ovarian cancer (OV 1607) À̹æÇö(°µ¿¼º½Éº´¿ø)
±³À°½Ã°£ 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 13:45~14:00 HIPEC for platinum sensitive recurrent EOC (OV 1603) ±èÈñ½Â(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 14:00~14:15 Minimally invasive surgery in ovarian cancer (OV 1610) ¹é¹ÎÇö(ÇѸ²´ë¼º½Éº´¿ø)
Åä·Ð 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 14:15~14:25 Discussion ()
±³À°½Ã°£ 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 14:25~14:45 Perspective of individualized molecularly targeted therapy of ovarian cancer based on genomic profile noriomi Matsumura(Kinki University Japan)
±³À°½Ã°£ 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 14:45~15:05 Genomic/epigenomic characterization of high grade serous ovarian carcinoma, leading to an investigator-initiated phase 2 clinical trial on basis of NGS-based biomarker Katsutoshi Oda(Tokyo University Japan)
Åä·Ð 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 15:05~15:15 Discussion ()
ÈÞ½Ä 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 15:15~15:35 Coffee Break ()
±³À°½Ã°£ 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 15:35~15:50 ³¼Ò¾Ï Ä¡·á¿ë Â÷¼¼´ë¼öÁö»ó¼¼Æ÷ Ç׾Ϲé½Å ÀÌÇö¾Æ(ÆĹ̼¿)
Åä·Ð 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 15:50~16:00 Discussion ()
±³À°½Ã°£ 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 16:00~16:15 Oncolytic virus immunotherapy: Pexa-Vec and its place in the Immuno-Oncology combination regimens ±ÇÇõÂù(½Å¶óÁ¨)
Åä·Ð 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 16:15~16:25 Discussion ()
±³À°½Ã°£ 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 16:25~16:40 Development of anti-PD-L1, immuno-oncology antibody, KL001-13 ±è´ëÈñ(½ºÅ©¸³½ºÄÚ¸®¾ÆÇ×ü¿¬±¸¿ø)
Åä·Ð 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 16:40~16:50 Discussion ()
±³À°½Ã°£ 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 16:50~17:05 Thoracic Radiation in EOC ±è¼¼ÀÍ(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 17:05~17:15 Discussion ()
±³À°½Ã°£ 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 17:15~17:30 Proper Treatment of Incidental Immature Teratoma G1 ¿À¿µÅÃ(°í´ë±¸·Îº´¿ø)
Åä·Ð 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 17:30~17:40 Discussion ()
±³À°½Ã°£ 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 17:40~17:55 PembrolizumabÀÇ Ä¡·á È¿°ú ¿¹ÃøÀ» À§ÇÑ biomarker Ž»ö Á¶ÀçÇö(¼¿ï´ëº´¿ø)
Åä·Ð 02-17 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 17:55~18:05 Discussion ()